|
|||||
|
|
Safety of PEGylated recombinant human full‐length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates |
|
| Authors: | R. Stidl S. Fuchs M. Bossard J. Siekmann P. L. Turecek M. Putz |
| Affiliation: | 1. Baxalta Innovations GmbH, Vienna, Austria;2. Nektar Therapeutics, Huntsville, AL, USA |
| Abstract: | |
| Keywords: | BAX 855 conjugation factor VIII haemophilia PEG safety |